T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities
As the number of recipients of chimeric antigen receptor (CAR) T-cell therapies has rapidly increased, sporadic reports of T-cell lymphomas arising de novo
Related Articles
FDA approves ensartinib for ALK-positive locally advanced or metastati
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Nature – Whole-genome sequencing of matched serial tumours from patients identifies two key mutagenic factors (APOBEC3 and chemotherapy) and extrachromosomal DNA-forming structural variants that…
Circumventing Cancer Resistance
Traditional and new cancer therapies often become stymied due to tumor resistance, but why resistance arises and how to avoid it remain important questions in…
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
Isshiki et al. demonstrate that EZH2 inhibitors re-activate immune synapse functions between B cell lymphomas and T cells, sensitizing lymphomas to T cell immunotherapies. EZH2 inhibition enhances killing…
NOT-OD-25-047: 2024 NIH Public Access Policy
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: 2024 NIH Public Access Policy NOT-OD-25-047. OD
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Patients with follicular lymphoma (FL) who progress within 24 months of front-line therapy (POD24) have poor outcomes, but clinical factors predicting earl
Sludinājumi – SS.LV
Sludinājumi Latvija un Rīga. Vislielākais sludinājumu serveris Latvijā. Vieglie auto, vakances un darbinieku meklēšana, kravas automašīnas, motocikli un velosipēdi, autoserviss un rezerves daļas. Аpmācība un…
Ivermectin: Dr. Pierre Kory and the Wonder Drug That Wasn’t – WhoWhatWhy
Ivermectin has fused with MAGA politics.
Hematologists Should Consider Sitosterolemia in Patients with Hemolytic Anemia, Thrombocytopenia, and High Cholesterol | ASH Clinical News | American Society of Hematology
Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. Population: Roughly 1 in 200,000 people across ethnicities; may present…
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
Human epidermal growth factor receptor 2 (HER2) overexpression or amplification (ERBB2amp) are biomarkers for approved anti-HER2 therapies. ERBB2amp may better predict response compared with immunohistochemistry…
